Saturday 17 October 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024. In the quarter to June 2026, revenue grew 3.50%, EPS grew 41.5% and free cash flow grew 4.40%, each against the same quarter a year earlier.
3.47
0.14
−3.88%
Follow PRME
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 14.52 | 5.54 | 2.56 | 1.11 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 21.73 | 21.48 | 9.77 | 6.94 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 150 | 175 | 234 | 214 | 146 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 5 | — | — | — | 3 | 5 | ||||
| Gross margin, % | — | — | — | — | 100.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | (3) | (2) | (166) | (123) | (198) | (196) | (201) | |||||
| EBT margin, % | — | — | — | 0.00 | (29.62) | 0.00 | 0.00 | 0.00 | (6,566.61) | (4,342.44) | |||||
| Net income | — | — | — | (3) | (3) | (165) | (122) | (198) | (196) | (201) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 2 | 1 | 3 | 5 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 1.97 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | ||||
| Earnings | — | — | — | (0.03) | (1.29) | (12.75) | (4.19) | (2.18) | (1.65) | (1.35) | |||||
| Cash flow | — | — | — | (0.01) | (2.10) | (2.63) | (3.89) | (1.82) | (1.04) | (1.09) | |||||
| Capex | — | — | — | 0.00 | (0.24) | (0.32) | (0.47) | (0.10) | (0.06) | (0.03) | |||||
| Free cash flow | — | — | — | (0.01) | (2.34) | (2.95) | (4.36) | (1.91) | (1.10) | (1.12) | |||||
| Book value | — | — | — | 0.00 | 0.00 | 18.47 | 9.33 | 1.46 | 1.29 | 0.81 | |||||
| Shares, m | — | — | — | 96 | 3 | 13 | 34 | 91 | 119 | 149 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | — | — | — | 0.00 | 111.44 | |||||
| P/B | — | — | — | — | 0.00 | — | — | — | 2.26 | 4.27 | |||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | 0.00 | 73.08 | |||||
| EV/FCF | — | — | — | — | (1.55) | — | — | — | (1.20) | (2.03) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (6) | (34) | (132) | (165) | (123) | (163) | ||||
| Capex | — | — | — | — | (1) | (4) | (16) | (9) | (7) | (5) | |||||
| Free cash flow | — | — | — | (1) | (6) | (38) | (148) | (174) | (130) | (167) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 34 | 213 | 270 | 87 | 174 | 144 | ||||
| Total debt | — | — | — | — | — | 10 | 29 | — | — | — | |||||
| Net debt | — | — | — | — | (53) | (270) | (294) | (122) | (190) | (178) | |||||
| Shareholders’ equity | — | — | — | — | — | 240 | 316 | 133 | 153 | 121 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | 0.00 | (121.99) | (42.89) | (71.51) | (79.73) | (62.83) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (325.92) | (1,122.17) | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | 0.00 | 239.27 | (177.48) | (88.19) | (136.88) | (146.81) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Prime Medicine, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DSGN Design Therapeutics, Inc. | $655.9M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | |
| AVTX Avalo Therapeutics, Inc. | $644.1M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $628.6M | — (loss-making) | — (loss-making) | −73.88% (below 0%: shrinking) | n/m | −17.59% (below 0%: shrinking) | 100.00% | (3,248.33%) | Compare |
| Median of peers | $668.1M | — | — | −18.97% | — | −74.80% | 62.35% | 0.00% |
Prime Medicine, Inc. (PRME) key facts
- Strength: Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024.
- Prime Medicine, Inc. (PRME) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PRME traded at $3.47, a market capitalization of $654.8 million.
- Return on equity was −146.8% and debt-to-equity 0.00.
- Its Altman Z-score is −3.72 (distress zone) for fiscal 2025.